Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Paul C. Hetzel"'
Publikováno v:
American Journal of Kidney Diseases. 44:e50-e58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce2f1f53cd8ad5486e230615b85b233b
https://doi.org/10.1016/s0272-6386(04)00985-0
https://doi.org/10.1016/s0272-6386(04)00985-0
Autor:
M. L. Johnson, Annesandra E. Podgurski, Frederick A. Flatow, Ralph N. Otto, Michael J. Warzynski, Paul C. Hetzel, Richard H. Steingart, Michael H. Rosen, Charles F. White
Publikováno v:
Leukemia Research. 15:357-365
We have noted what other preliminary reports have also described as a new specificity of the MY4 monoclonal antibody from Coulter Immunology which previously was designated to only have myelogenous CD14 specificity. The MY4 marker appears to characte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6bcb4e71c11143153c273ab126d3dcb
https://doi.org/10.1016/0145-2126(91)90011-h
https://doi.org/10.1016/0145-2126(91)90011-h
Publikováno v:
American journal of kidney diseases : the official journal of the National Kidney Foundation. 44(4)
Mitomycin-induced hemolytic uremic syndrome (HUS) is a life-threatening complication of this therapy, and increased levels of circulating immune complexes and hypocomplementemia have been found in some patients. We further characterize the role of im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::87a1127e94c3340f58eaa113546a2a64
https://pubmed.ncbi.nlm.nih.gov/15384034
https://pubmed.ncbi.nlm.nih.gov/15384034
Publikováno v:
Journal of Clinical Oncology. 22:2744-2745
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7db4bc047e7e845925b4ba5317af7cbd
https://doi.org/10.1200/jco.2004.10.130
https://doi.org/10.1200/jco.2004.10.130
Publikováno v:
American Journal of Clinical Pathology. 91:227-231
A patient with prolymphocytic leukemia was immunophenotyped by whole blood and Ficoll-Hypaque methods. Discordance was noted between the two methods, especially for the HLE1, B1, I2, and T1B monoclonal markers. The disparity in results reflected the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f83a6825e2096a99626d3d73c99d1df1
https://doi.org/10.1093/ajcp/91.2.227
https://doi.org/10.1093/ajcp/91.2.227